NCT03413761 is a clinical trial in Node Positive Breast Cancer, sponsored by Roswell Park Cancer Institute.

Who is sponsoring NCT03413761?

NCT03413761 is sponsored by Roswell Park Cancer Institute.

What condition does NCT03413761 study?

NCT03413761 studies Node Positive Breast Cancer, Node Negative Breast Cancer.

Is NCT03413761 still recruiting?

NCT03413761 is currently completed. Last updated 8 August 2022.

Last reviewed 2022-08-08 · How we verify

NCT03413761

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Antioxidant Supplements, Genetics and Chemotherapy Outcomes

Completed Last updated 8 August 2022

What this trial tests

trial in Node Positive Breast Cancer in 1,771 participants. Completed in 12 November 2013.

Timeline

18 December 2004

Primary endpoint
12 November 2013

12 November 2013

Quick facts

Lead sponsor	Roswell Park Cancer Institute
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,771
Start date	18 December 2004
Primary completion	12 November 2013
Estimated completion	12 November 2013

Conditions studied

Node Positive Breast Cancer — all drugs for Node Positive Breast Cancer →
Node Negative Breast Cancer — all drugs for Node Negative Breast Cancer →

Sponsor

Roswell Park Cancer Institute

Who can join

18 and older, any sex, with Node Positive Breast Cancer or Node Negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will investigate the null hypothesis that use of antioxidant supplements during adjuvant chemotherapy will have no impact on toxicities and disease-free, as well as overall, survival, and also evaluate the role of polymorphisms in genes related to oxidative stress in relation to treatment outcomes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221).
Mongiovi JM, Zirpoli GR, Cannioto R, Sucheston-Campbell LE, et al · · 2018 · cited 15× · PMID 30486865 · DOI 10.1186/s13058-018-1077-9

Verify or expand the search:

Other Roswell Park Cancer Institute trials

Trials by the same sponsor.

NCT07489287 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer · Phase 1 · not yet recruiting
NCT06943664 — Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-I · Phase 2 · not yet recruiting
NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids · Phase 2 · not yet recruiting
NCT06334016 — Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream · EARLY_PHASE1 · not yet recruiting
NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03413761 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Roswell Park Cancer Institute
Last refreshed: 8 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03413761.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing